Denosumab - where does it stand in the GIOP armamentarium?

Abstract

We read with interest, the article on Denosumab vs. risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial by Saag KG et\xa0al. [1] Osteoporosis in a setting of glucocorticoid-induced osteoporosis (GIOP) is challenging because of issues with drug adherence (due to the pill burden) and the presence of multiple comorbidities. Denosumab is a welcome addition in the armamentarium of this disease due to its once-in-six months dosing, which is associated with better adherence than bisphosphonates[2] and its renal safety [3]. However, certain clarifications may further help the readers to understand its applicability and choosing it as an alternative therapy.